Alfonse Muto and Alfonse J. Muto, Pharm.D. register with the FDA shortly after the passage of Section 503B under the FD&C Act, establishing Pine Pharmaceuticals in a 5,000 sq. ft. facility.

Pine continues its growth within the industry by launching six products addressing new therapeutic areas, expanding its impact on patient care.

Pine releases six new ophthalmology products, enhancing its ability to partner with ambulatory surgery centers.

Pine diversifies its catalog with five additional custom compounds, offering physicians new ready-to-use options to address individual patient needs more effectively.

Pine unveils a new 25,000 sq. ft. cGMP-compliant facility, doubling its previous facility size and workforce and paving the way for the launch of four new products. 

Pine aids in the COVID-19 pandemic relief efforts, supplying hand sanitizer nationwide. 

Pine triples in size with a 50,000 sq. ft. expansion, enabling additional manufacturing, quality control, and warehousing capabilities. This growth strengthens its ability to address drug shortages and meet increasing demand.

Pine expands its presence in the hospital market, introducing nine ready-to-administer IV bags. A new quality control lab is also established, enhancing its in-house testing capabilities.

Today, Pine partners with hospitals, surgery centers, and specialty practices nationwide, distributing millions of units yearly.